Skip to main content
رجوع
ULIHF logo

The United Laboratories International Holdings Limited

جودة البيانات: 100%
ULIHF
OTC Healthcare Drug Manufacturers - Specialty & Generic
KWD 1.70
KWD 0.00 (0.00%)
القيمة السوقية: 3.35B
نطاق اليوم
KWD 1.70 KWD 1.75
نطاق 52 أسبوعًا
KWD 1.43 KWD 2.35
حجم التداول
29
متوسط 50 يوم / 200 يوم
KWD 1.79 / KWD 1.85
الإغلاق السابق
KWD 1.70

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 1.3 0.4
P/B 0.2 2.9
ROE % 19.6 3.7
Net Margin % 19.3 3.9
Rev Growth 5Y % 11.9 10.0
D/E 0.2 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2029 KWD 0.000
KWD 0.000 – KWD 0.000
 17 B 0
FY2028 KWD 1.524
KWD 1.291 – KWD 1.722
 15 B 1
FY2027 KWD 1.366
KWD 1.158 – KWD 1.544
 14 B 1

النقاط الرئيسية

Revenue grew 11.91% annually over 5 years — strong growth
ROE of 19.61% — decent returns on equity
Net margin of 19.33% shows strong profitability
Debt/Equity of 0.22 — conservative balance sheet
Generating 1.33B in free cash flow
P/E of 1.26 — trading at a low valuation

النمو

Revenue Growth (5Y)
11.91%
Revenue (1Y)0.14%
Earnings (1Y)-1.54%
FCF Growth (3Y)3.07%

الجودة

Return on Equity
19.61%
ROIC13.32%
Net Margin19.33%
Op. Margin22.65%

الأمان

Debt / Equity
0.22
Current Ratio1.83
Interest Coverage89.14

التقييم

P/E Ratio
1.26
P/B Ratio0.23
EV/EBITDA0.06
Dividend Yield0.06%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0.14% Revenue Growth (3Y) 10.18%
Earnings Growth (1Y) -1.54% Earnings Growth (3Y) 29.70%
Revenue Growth (5Y) 11.91% Earnings Growth (5Y) 39.47%
Profitability
Revenue (TTM) 13.76B Net Income (TTM) 2.66B
ROE 19.61% ROA 10.30%
Gross Margin 44.21% Operating Margin 22.65%
Net Margin 19.33% Free Cash Flow (TTM) 1.33B
ROIC 13.32% FCF Growth (3Y) 3.07%
Safety
Debt / Equity 0.22 Current Ratio 1.83
Interest Coverage 89.14 Dividend Yield 0.06%
Valuation
P/E Ratio 1.26 P/B Ratio 0.23
P/S Ratio 0.24 PEG Ratio -3.10
EV/EBITDA 0.06 Dividend Yield 0.06%
Market Cap 3.35B Enterprise Value 180.04M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 13.76B 13.74B 11.33B 9.70B 8.77B
Net Income 2.66B 2.70B 1.58B 988.10M 702.99M
EPS (Diluted) 1.46 1.49 0.87 0.54 0.40
Gross Profit 6.08B 6.33B 4.97B 4.21B 3.81B
Operating Income 3.12B 3.29B 2.02B 1.41B 1.23B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 25.83B 21.02B 18.98B 16.33B 14.96B
Total Liabilities 11.40B 8.27B 8.37B 6.99B 6.35B
Shareholders' Equity 14.39B 12.73B 10.61B 9.34B 8.61B
Total Debt 3.16B 1.50B 2.46B 1.84B 2.21B
Cash & Equivalents 6.33B 4.26B 4.74B 3.33B 3.00B
Current Assets 16.07B 13.79B 12.51B 9.99B 8.22B
Current Liabilities 8.77B 6.63B 7.03B 6.54B 4.86B

درجات الاستراتيجيات

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#238 of 820
54
Custom Contrarian Investing (David Dreman)
#458 of 658
16
Value Defensive Investing (Benjamin Graham)
#114 of 708
53

النشاط الأخير

دخل Deep Value Investing (Seth Klarman)
Mar 24, 2026
دخل Contrarian Investing (David Dreman)
Mar 24, 2026
دخل Defensive Investing (Benjamin Graham)
Mar 24, 2026